InvestorsHub Logo
Followers 62
Posts 7524
Boards Moderated 1
Alias Born 01/02/2003

Re: Tatsumaki post# 419062

Tuesday, 12/12/2023 6:03:02 AM

Tuesday, December 12, 2023 6:03:02 AM

Post# of 424759
Tats...Apparently, from your comments, you did not read my recent post...so I'll repeat it...QUOTE..."NICE recommends that only one omega-3 fatty acid compound is recommended in specific clinical circumstances – icosapent ethyl [Vazkepa®] (NICE TA805), and that all other omega-3 fatty acid compounds are NOT suitable for prescribing"

Astra Zeneca knows this from their expensive failure with Omacor...How come you don't?...You seem to be on team Nissin in bashing Vascepa.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News